Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161197 | 0.87 | MAPT (0.41) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10161226 | 0.86 | MAPT (0.40) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10160881 | 0.86 | NSD2 (0.40) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10160884 | 0.82 | MAPT (0.41) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10160979 | 0.80 | MAPT (0.43) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10160471 | 0.79 | MAPT (0.42) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10160980 | 0.78 | MEN1 (0.39) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10160931 | 0.78 | ALDH1A1 (0.39) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10160947 | 0.78 | ALOX5 (0.36) | MAPTSMN1; SMN2NPC1CYP1A2GAA | |
| SCHEMBL10161192 | 0.73 | MAPT (0.36) | MAPTSMN1; SMN2NPC1CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| WO-2010132670-A2 | PENTACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TSLP, IL5, IL17A | MAPT 734/4885SMN1; SMN2 3883/4885NPC1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.